Findings indicate that neoadjuvant chemotherapy (ctx) for resectable gastric cancer results in significantly longer overall survival (OS) compared to neoadjuvant chemoradiation (crtx). Analysis of 14,266 patients revealed a 20%-30% improvement in 5-year OS for the ctx group, despite a higher prevalence of complete pathological response in the crtx cohort. The study posits that current AJCC staging may overestimate survival for patients undergoing crtx and introduces a nomogram for enhanced OS prediction.
• Why it matters: Neoadjuvant treatments impact survival rates in gastric cancer patients.
Journal Article by Takahashi H, Nakauchi M, Hiotis S and Datta R in J Surg Oncol
© 2024 Wiley Periodicals LLC.